IMMIX BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 6.00K shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 21.48K shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 400.00 shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 4.90K shares, a 487.53% increase from fiscal 2024.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 834.00 shares, a 38.27% decline from fiscal 2023.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.35K shares, a 99.04% decline from fiscal 2022.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 140.99K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 6.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | 27.88K shares derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | 21.48K shares 10-Q · filed 2026-05-07 | |
| 2025-12-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | 4.90K shares 10-K/A · filed 2026-03-27 |
| 2025-09-30 | 400.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | |
| 2024-12-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | 834.00 shares 10-K/A · filed 2026-03-27 |
| 2024-09-30 | -417.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | |
| 2024-03-31 | 1.25K shares 10-Q · filed 2024-05-09 | |
| 2023-12-31 | 1.35K shares 10-K · filed 2025-03-25 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 140.99K shares 10-K · filed 2024-03-29 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |